CLN GPW sWIG80 Periodic report · PAP Biznes
Celon Pharma SA (CLN) · Q1 2026 results
Share price: 16.30 zł · 2026-11-10
Results Q1 2026 vs Q1 2025 · year over year · published 20 May 2026 and 21 May 2025
Net income turned to a profit from a loss a year earlier. The report's language is unchanged.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Turned profit
Net income vs Q1 2025
Net income 162.6M vs -25.1M
Revenue +25.4%
2 · How the report reads
Unchanged
Language tone vs last period
Report language: upbeat for a company report — about as upbeat as in Q1 2025.
Weak signal: formal report language, not a call.
3 · What stood out
Key theme
Novohale will transition from the equity method to being valued at fair value as a financial asset, changing how investment results and fair value…
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
16.30 zł
close of 2026-11-10
Revenue growth, 3 years
+1.5% a year
compound annual rate (CAGR)
Read between the lines
No major shifts flagged this period.
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q1 2026. Ring: Q1 2025.
Upbeat for a company report — about as upbeat as in Q1 2025. Periodic reports carry legally required risk wording, so their tone moves little and is a weak signal.
Sentences that drove the tone
“However, in view of the rapid pace of events, the Company does not rule out the occurrence of factors that may negatively impact the Company's financial result in subsequent periods, especially due to the possible negative impact on...”
“At the same time, taking into account the high level of uncertainty in the macroeconomic and political environment, the Management Board emphasizes that this assessment was made based on the best available information and realistic development scenarios...”
“Continued dynamic growth of the generic drugs segment, including in particular the further growth of Salmex's global reach and sales”
Full figures
PLN · PAP Biznes report (2026-05-20)
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | 61.9M | 49.3M | +25.4% |
| Operating income | -6.0M | -18.8M | Loss narrowed |
| Net income | 162.6M | -25.1M | Turned profit |
| EPS | 3.06 | -0.47 | Turned profit |
| P/E | 12-mo loss | 12-mo loss | — |
Topics
Topics are drawn from the full report text, not management commentary.
Most discussed now
- The investment implementation should support the further scaling of the Group's activities, increasing operational independence in the…
- The Company informed about the conclusion of the Agreement in current report no. 4/2026 dated March 9, 2026.
- In the event that other innovative projects of the Company reach advanced stages of clinical development
- At the same time, the innovative segment recorded growth - revenues increased from 0.4 million PLN to 8.4 million PLN
Faded since Q1 2025
- Fading Qualification of three Celon Pharma S.A. projects for funding
- Fading Concise description of the Issuer's significant achievements or failures during the period covered by the financial statements, together…
- Fading As part of the next stage, a demerger by spin-off of the Issuer and a transfer of the Business is planned.
- Fading As part of the implementation of the Incentive Programs, eligible persons may acquire the right to subscribe for Series A warrants…
Latest announcements
Official filings, newest first.
- Half-year report · ESPI periodic
- Uzyskanie pozytywnej opinii Jednostki Notyfikowanej (Notified Body Opinion) dla wstrzykiwacza stanowiącego element rozwoju produktu semaglutyd Celon Pharma (projekt Reduzek) · ESPI 20/2026
- Powiadomienie o transakcji dotyczącej warrantów subskrypcyjnych Celon Pharma S.A. · ESPI 19/2026
- Przydział warrantów subskrypcyjnych serii A osobie uprawnionej w ramach Programu Motywacyjnego dla Członków Zarządu Spółki za rok 2026 · ESPI 18/2026
- Pozytywne wyniki badania biorównoważności Semaglutydu Celon (Reduzek) · ESPI 17/2026
- Oświadczenie KDPW o dokonaniu asymilacji 55.000 akcji serii C z akcjami Spółki znajdującymi się w obrocie giełdowym · ESPI 16/2026
- Dopuszczenie i wprowadzenie akcji zwykłych na okaziciela serii C Spółki do obrotu giełdowego · ESPI 15/2026
- Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Celon Pharma S.A. w dniu 24 czerwca 2026 r. · ESPI 14/2026